CAS Medical Systems, Inc. (NASDAQ:CASM) – Stock analysts at Zacks Investment Research raised their FY2017 EPS estimates for shares of CAS Medical Systems in a research report issued to clients and investors on Monday. Zacks Investment Research analyst B. Marckx now expects that the medical technology company will post earnings per share of ($0.28) for the year, up from their previous forecast of ($0.36). Zacks Investment Research also issued estimates for CAS Medical Systems’ Q4 2017 earnings at ($0.08) EPS and FY2018 earnings at ($0.22) EPS.

CAS Medical Systems (NASDAQ:CASM) last announced its quarterly earnings data on Thursday, November 9th. The medical technology company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.05. The firm had revenue of $4.53 million during the quarter, compared to analysts’ expectations of $4.47 million.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/22/fy2017-earnings-forecast-for-cas-medical-systems-inc-issued-by-zacks-investment-research-casm.html.

Separately, ValuEngine cut shares of CAS Medical Systems from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

Shares of CAS Medical Systems (NASDAQ CASM) opened at $0.70 on Wednesday. The company has a debt-to-equity ratio of -0.56, a quick ratio of 2.12 and a current ratio of 2.46. CAS Medical Systems has a 52 week low of $0.61 and a 52 week high of $1.78.

An institutional investor recently bought a new position in CAS Medical Systems stock. Stonepine Capital Management LLC bought a new stake in shares of CAS Medical Systems, Inc. (NASDAQ:CASM) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 900,366 shares of the medical technology company’s stock, valued at approximately $1,044,000. CAS Medical Systems makes up approximately 0.6% of Stonepine Capital Management LLC’s portfolio, making the stock its 23rd largest position. Stonepine Capital Management LLC owned 3.29% of CAS Medical Systems at the end of the most recent quarter. 24.63% of the stock is owned by institutional investors.

CAS Medical Systems Company Profile

CAS Medical Systems, Inc is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products for patient care. The Company designs, manufactures and distributes the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. It operates through Tissue Oximetry Monitoring, which includes sales of its FORE-SIGHT tissue oximeter monitors, sensors and accessories.

Earnings History and Estimates for CAS Medical Systems (NASDAQ:CASM)

Receive News & Ratings for CAS Medical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAS Medical Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.